Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events (MACE) by 15% (HR=0.85, CI: 0.78, 0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, stroke, death from coronary heart disease (CHD) or unstable angina requiring hospitalization. Data were presented at the American College of Cardiology meeting in Orlando.

Armed with the cardiovascular outcomes data and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), the partners also proposed

Read the full 1012 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE